全文获取类型
收费全文 | 20494篇 |
免费 | 2048篇 |
国内免费 | 842篇 |
学科分类
医药卫生 | 23384篇 |
出版年
2024年 | 177篇 |
2023年 | 723篇 |
2022年 | 1347篇 |
2021年 | 1486篇 |
2020年 | 1262篇 |
2019年 | 969篇 |
2018年 | 878篇 |
2017年 | 879篇 |
2016年 | 816篇 |
2015年 | 719篇 |
2014年 | 1266篇 |
2013年 | 1605篇 |
2012年 | 1114篇 |
2011年 | 1190篇 |
2010年 | 923篇 |
2009年 | 884篇 |
2008年 | 848篇 |
2007年 | 866篇 |
2006年 | 701篇 |
2005年 | 629篇 |
2004年 | 532篇 |
2003年 | 459篇 |
2002年 | 425篇 |
2001年 | 307篇 |
2000年 | 255篇 |
1999年 | 237篇 |
1998年 | 207篇 |
1997年 | 186篇 |
1996年 | 177篇 |
1995年 | 142篇 |
1994年 | 134篇 |
1993年 | 114篇 |
1992年 | 97篇 |
1991年 | 85篇 |
1990年 | 81篇 |
1989年 | 75篇 |
1988年 | 73篇 |
1987年 | 50篇 |
1986年 | 59篇 |
1985年 | 77篇 |
1984年 | 65篇 |
1983年 | 48篇 |
1982年 | 53篇 |
1981年 | 36篇 |
1980年 | 31篇 |
1979年 | 20篇 |
1978年 | 21篇 |
1977年 | 10篇 |
1976年 | 17篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
目的探讨化浊解毒方治疗溃疡性结肠炎(UC)的治疗作用及机制。方法120例UC患者按照随机数字表法分为观察组、对照组各60例。观察组予中药化浊解毒方口服,每日1剂,早晚2次温服;对照组予美沙拉嗪肠溶片口服,1.0 g/次,3次/d。2组疗程均4周。对比2组治疗前后Geboes指数、结肠镜下黏膜表现、生活质量评分、疾病活动指数及血清炎性因子IL-8、IL-35水平,凝血指标血清FIB水平,统计治疗后1年内复发情况。结果治疗后,观察组Geboes指数、疾病活动指数及血清炎性因子IL-8水平、凝血指标血清FIB水平均较本组治疗前降低,生活质量评分、血清炎性因子IL-35水平升高(P<0.05);且观察组治疗后疾病活动指数及血清炎性因子IL-8水平、凝血指标血清FIB水平均低于对照组,生活质量评分、血清炎性因子IL-35水平均高于对照组(P<0.05)。与对照组相比,治疗组糜烂、溃疡改善不明显(P>0.05),充血水肿、颗粒样变等肠镜表现改善情况均优于对照组(P<0.05)。治疗结束1年观察组复发率为10.64%,对照组为23.53%,2组差异有统计学意义(P<0.05)。结论化浊解毒方能改善UC患者临床症状,修复肠黏膜病理损伤,降低复发率;其机制可能与调节血清炎性因子IL-8、IL-35和凝血因子FIB水平有关。 相似文献
2.
子宫内膜异位症其异位内膜组织虽然在形态学上呈良性表现,却具有类似恶性肿瘤的生物学特性。中医学一般认为,“正虚伏邪”为恶性肿瘤的病机特点;那么,肾虚血瘀既属于“正虚伏邪”的范畴,又体现了EMs发病学和疾病发生、发展过程中的主要特点。在“病证相应”的中医治则之下,补肾化瘀法的临床疗效主要表现为:缓解痛经症状、提高受孕率,以及调整月经周期。本文基于EMs与恶性肿瘤的相关性,通过分析补肾化瘀法治疗EMs的理论依据及其抑制异位内膜侵袭的调控机制,主要包括解除免疫抑制、阻断局部微血管新生等,旨在阐明其疗效显著的原因,为临床推广提供可靠的基础研究证据。 相似文献
3.
前后挤压型骶骨Ⅱ区骨折与骶丛神经损伤的关系 总被引:1,自引:0,他引:1
目的 探讨前后挤压致骶骨Ⅱ区骨折造成骶丛神经损伤的机制。方法 经甲醛短期(1年内)浸泡固定的国人尸体6具,12侧。解剖保护骶丛神经,制成前后挤压型暴力致骶Ⅱ区骨折模型,定量测量不同骨折移位时骶丛神经被拉长的距离。另外,利用X线片观察骶从神经受压情况。结果 随耻骨联合分离逐渐增大,骶丛神经张应变呈直线相关逐渐加大,以S1,S4为最显著,且可造成神经的刺伤,多见于L5和S1,X线未发现骶丛神经受压表现。结论 前后挤压型暴力致骶骨Ⅱ区骨折神经损伤以牵拉伤为丰,以S1,S4为主,且与骨折移位程度成正相关关系。神经的刺伤,多见于骨折移位较大的L5和S1。 相似文献
4.
R. H. Wiesner B. J. Steffen K. M. David A. H. Chu R. D. Gordon J. R. Lake 《American journal of transplantation》2006,6(7):1609-1616
Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described. To investigate the risk of LAR (rejection > or = 6 months post-transplantation) data from the Scientific Registry of Transplant Recipients (SRTR) were used. We studied adult primary liver transplant recipients transplanted between June 1, 1995, and April 30, 2004, with hepatitis C virus (HCV) (n = 3356), hepatitis B virus (HBV) (n = 550) or a nonviral (n = 5740) primary cause of liver disease who were recorded as receiving continuous 3-(MMF + Tacro + steroids) versus 2-drug (Tacro + steroids) therapy for at least 6 months immediately post transplantation. Kaplan-Meier analysis showed significantly lower LAR rates 4 years post-transplant in 3- versus 2-drug HCV, HBV and nonviral disease patients. Multivariate regression confirmed 3- versus 2-drug therapy to be associated with a decreased risk of LAR. Late graft survival was significantly lower at 4 years post-transplant for patients with LAR 6-12 months post-transplantation versus patients with early rejection (78.0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes. 相似文献
5.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
6.
Long-term neurotoxicity of chlorpyrifos: spatial learning impairment on repeated acquisition in a water maze. 总被引:2,自引:0,他引:2
Fernando Ca?adas Diana Cardona Eva Dávila Fernando Sánchez-Santed 《Toxicological sciences》2005,85(2):944-951
Organophosphate compounds are cholinesterase inhibitors widely used in agriculture, industry, household products, and even as chemical weapons. Their major mechanism of acute toxic action is the inhibition of acetylcholinesterase, which is responsible for the degradation of the neurotransmitter acetylcholine. An organophosphorus ester-induced chronic neurotoxicity (OPICN) syndrome has been proposed. The OPICN syndrome could result from both long-term exposure to subclinical doses of OPs and after acute poisoning. Development of animal models for the cognitive decline are required and could later help to elucidate the mechanisms involved in this long-term effect on the central nervous system. Previously, we have found performance decrements in a four-trial repeated acquisition spatial task in a water maze. The present study includes two experiments to extend the long-term behavioral effects observed. Rats were injected either once or twice with chlorpyrifos (CPF) and then tested months after in a two-trial repeated acquisition task in a water maze. Our results confirm and extend the long-term behavioral effects of subcutaneous administration of CPF. The two treatments used produced performance decrements that suggest functional central nervous system alterations. 相似文献
7.
Skoug John W. Borin Marie T. Fleishaker Joseph C. Cooper Anne M. 《Pharmaceutical research》1991,8(12):1482-1488
The mechanism of release from sustained-release adinazolam mesylate tablets was assessed by the Higuchi equation and by analysis of drug release profiles through 60% released using the Peppas equation. Computed values of the diffusional exponent, n, ranged from 0.59 to 0.66. Values of n in this range are consistent with a mixed mechanism of release, with diffusion of drug through the hydrated polymer matrix and relaxation of this matrix being the principal processes controlling release. The rate of in vitro drug release was increased for half tablets relative to whole tablets and is attributed to an increase in the surface to volume ratio of half tablets of about 16%. This increase in surface-to-volume ratio of half tablets was reflected by an increase in the constant, k, from the Peppas equation of 20–23% and by an increase in the slope of Higuchi plots of 12–18% for four lots of tablets. In vivo/in vitro relationships from two bioavailability studies were thoroughly evaluated. Using either a linear or a quadratic relationship, an in vivo/in vitro correlation exists for sustained-release adinazolam mesylate tablets. 相似文献
8.
9.
中医情志的发生机制刍议 总被引:1,自引:0,他引:1
在情志学说和脑主神明理论指导下对情志产生的生理机制作新的诠释。认为脑神的气化出入及整合作用是情志发生的生理基础 ;五脏所化的气血精津为情志发生的物质基础 相似文献
10.
To evaluate the long-term effects of entacapone on both mean daily 'on' time and health-related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing 'end-of-dose' motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12-month study was performed with an initial 3-month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries ('on' time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ-8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group ( P < 0.01). The improvement in 'on' time was significantly increased since the 3-month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ-8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing 'on' time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment. 相似文献